Kite Pharma Inc. thinks its autologous T cell technology can address multiple malignancies regardless of the underlying mechanism or biology. It says the platform has shown durable efficacy following a single dose in trials at the National Cancer Institute.

Kite was founded in 2009 to develop cancer immunotherapies and in 2011 licensed DC-AdGM-CAIX from the University of California, Los Angeles. The therapy comprises dendritic cells engineered to express a fusion protein of carbonic anhydrase IX (CAIX) and granulocyte macrophage colony-stimulating factor (GM-CSF; CSF2).